Akebia shareholders approve 18.9M share increase to 2023 Stock Incentive Plan

Akebia Therapeutics, Inc.

Shareholders approved amendment to 2023 Stock Incentive Plan to increase shares by 18,900,000 (102.75M for, 48.21M against).
Directors John P. Butler and Myles Wolf re-elected as Class II directors with over 119.9M votes each.
Advisory vote on executive compensation passed with 110.68M for, 39.01M against.
Ratification of Ernst & Young as auditor for 2025 passed with 178.59M for, 8.90M against.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.